skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Christine B. Hunter, R.N., C.C.R.C.

Instructor of Neurology

Clinical Service Area

Neurology

Graduate School

R.N., Houston Community College, Texas

Clinical Interests

Movement disorders including Parkinson's disease, essential tremor, dystonia, Tourette's syndrome and Huntington's disease

Research Interests

Experimental therapeutics and genetics of movement disorders

Contact Information

Christine B. Hunter, R.N., C.C.R.C.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-3951
Fax: 713-798-6808
Email:

Journal Publications (Selected out of 35)

  • Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol. 2014;:. [View journal article]
  • Pulliam CL, Eichenseer SR, Goetz CG, Waln O, Hunter CB, Jankovic J, et al. Continuous in-home monitoring of essential tremor. Parkinsonism Relat Disord. 2014;20(1):37-40. [View journal article]
  • Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210-5. [View journal article]
  • Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [View journal article]
  • Ondo WG, Hunter C, Ferrara JM, Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012;18(5):619-22. [View journal article]
  • Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650-4. [View journal article]
  • Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, et al. Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(2):117-8. [View journal article]
  • Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(3):315-9. [View journal article]
  • Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, et al. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19(6):606-17. [View journal article]
  • Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2009;82(3-4):201-7. [View journal article]

Book Chapters and Other Publications

  • Jankovic J, Hunter C. Psychogenic parkinsonism. In: Hallett M, Cloninger CR, Fahn S, Halligan P, Jankovic J, Lang AE, Voon V, editors. Psychogenic movement disorders and other conversion disorders. Cambridge, UK: 2011. p. 14-19.

Poster and Platform Presentations (Selected out of 49)

  • Pulliam CL, Eichenseer S, Goetz C, Waln O, Hunter C, Jankovic J, et al. Continuous home monitoring of essential tremor using motion sensors. Neurology. 2013;80(Meeting Abstracts 1):P05.035.
  • Baizabal Carvallo JF, Suresh K, Hunter C, Jankovic J. Flu-like and systemic symptoms following treatment with botulinum toxins. Mov Disord. 2012;27(Suppl 1):S422. [View poster]
  • Mehanna R, Hunter C, Davidson A, Ondo W, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2012;27(Suppl 1):S457. [View poster]
  • Shen V, Clarence-Smith K, Hunter C, Jankovic J. Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease. Mov Disord. 2012;27(Suppl 1):S59-60. [View poster]
  • Shen V, Clarence-Smith K, Hunter C, Jankovic J. Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease. Mov Disord. 2012;27(Suppl 1):S60. [View poster]
  • Shen V, Clarence-Smith K, Hunter C, Jankovic J. Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease. Mov Disord. 2012;27(Suppl 1):S60. [View poster]
  • York MK, Marsh L, Jimenez-Shahed J, Okun M, Moro E, Hunter C, et al. Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real world pre-operative practice patterns. Mov Disord. 2012;27(Suppl 1):S172. [Previously Presented] [View poster]
  • York MK, Marsh L, Jimenez-Shahed J, Okun M, Moro E, Hunter C, et al. Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real world pre-operative practice patterns. Mov Disord. 2012;27(4):e12. [View poster]
  • Clarence-Smith K, Shen V, Hunter C, Jankovic J. Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease (HD). Neurology. 2012;78(Meeting Abstracts 1):P06.039. [View poster]
  • Meunier C, Jennings D, Hunter C, Sherer T. Fox Trial Finder: An innovative web-based trial matching tool to facilitate clinical trial recruitment. Neurology. 2012;78(Meeting Abstracts 1):P02.241.

E-mail this page to a friend